The quality of medical services in pediatrics as an example for the availability of implantable venous port systems for the treatment of orphan diseases and cancer in children
Introduction The management of cancer and orphan diseases in children requires long term intravenous infusions of varying duration. Their successful implementation demands for sustainable venous access, which can be provided only with the help of implantable venous port systems. Aim There are presented data of the analysis of the quality of medical services on the example of the prevalence and availability of implantable venous port systems for the treatment of cancer and orphan diseases in children. Materials and Methods There were analyzed results of the use of different systems of the venous access in 428 patients with cancer and 11 patients with orphan diseases. The use of subclavian catheters in pediatric oncology was established to lead to disruption of treatment protocols in 45.9% of children with cancer. It is expedient to use implantable venous ports that are used only in the 13 Health centers of the Russian Federation, for which in 2014 there were bought 755 venous ports (49% - for Moscow clinics, 10.6% - in st. Petersburg and 40.4% - in other cities) and only 11 have been applied in patients with orphan diseases. conclusions The authors believe that the quality of care for children with cancer and orphan diseases can be significantly improved by the use of implantable venous port systems that improve the results of the treatment and bring them closer to those in developed countries.
About the authorsRykov M.Yu.
De Gaudo A., Di Filippo A. Device-related infections in critically ill patients. Part 1% prevention of catheter-related bloodstream infections. J. chemother. 2003; 15: 419-27.
Kite P., Dobbins B., Wilcox M. Rapid diagnosis of central venous catheter-related bloodstream infections without catheter removal. Lancet. 1999; 354 (9189): 1504-7.
Kolderhoff M., Zakrzewski J. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patient. int. J. Antimicrob. Agent. 2004; 24(9): 47-8.
D’Aco K., Underhill L., Rangachari L., Arn P., Gerald F. Cox. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur. J. Pediat. 2012; 171(7): 911-9.
Mendelsohn N.J., Harmatz P., Bodamer O. et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet. Med. 2010; 12: 816-22.
Mickley V. Central venous catheters: many questions, few answers. Nephrol. dial. Transplant. 2002; 17(7): 1368-73.
Moores C., Rogers J.G., McKenzie I.M., Brown T.C.K. Anaesthesia for children with mucopolysaccharidoses. Anaesth. intensive care. 1996; 24(9): 459-63.
Walder B., Pttet D. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect. control. hosp. Epidemiol. 2002; 23(9): 748-56.
Walker R.W.M., Darowski M., Morris P., Wraith J.E. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia. 1994; 49(12): 1078-84.
Wilson S.E. Vascular Access. Principles and Practice. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2010.
Баранов А.А., Намазова-Баранова Л.С., Ильин А.Г., Булгакова В.А., Антонова Е.В., Смирнов И.Е. Научные исследования в педиатрии: направления, достижения, перспективы. Российский педиатрический журнал. 2013; 5: 4-14.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.